SFN 2025
Nov 15 - 19, 2025 | San Diego, CA
The agents listed below are currently under investigation. Their safety and efficacy have not been established.
Poster
ARV-102, a PROTAC LRRK2 Degrader, Modulates Pathways Associated With Parkinson’s Disease and Progressive Supranuclear Palsy: Proteomic Analyses of CSF From Non-human Primates and Healthy VolunteersA Hendricson et al.